301201.SZ

Aug 25, 2026, 08:01 UTC

Chengda Pharmaceutical announced its H1 2026 results: revenue of 255 million yuan, up 40.03% year-on-year; net profit attributable to shareholders of 2.2997 million yuan, down 82.07% year-on-year; net loss attributable to shareholders excluding non-recurring items of 5.2726 million yuan, down 281.87% year-on-year. The company plans no cash dividend, no bonus shares, and no capital reserve conversion.